GT Biopharma: Strong Q3 Performance and Promising Pipeline Progression Justify Buy Rating
HC Wainwright & Co. Reiterates Buy on GT Biopharma, Maintains $5 Price Target
GT Biopharma Analyst Ratings
EF Hutton Reiterates Hold on GT Biopharma, Maintains $2 Price Target
GT Biopharma Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), IGM Biosciences (IGMS) and GT Biopharma (GTBP)
HC Wainwright & Co. Reiterates Buy on GT Biopharma, Maintains $5 Price Target
HC Wainwright & Co. Reiterates Buy on GT Biopharma, Maintains $5 Price Target
GT Biopharma (GTBP) Receives a Buy From H.C. Wainwright
Analysts Offer Insights on Healthcare Companies: Cara Therapeutics (CARA), GT Biopharma (GTBP) and Spruce Biosciences (SPRB)
GT Biopharma (GTBP) Gets a Buy From H.C. Wainwright
EF Hutton Keeps Their Hold Rating on GT Biopharma (GTBP)
EF Hutton Reiterates Hold on GT Biopharma, Maintains $2 Price Target
GT Biopharma Analyst Ratings
EF Hutton Initiates Coverage On GT Biopharma With Hold Rating, Announces Price Target of $2
Fate Therapeutics Extends Losses as Goldman Initiates at Sell
HC Wainwright Adjusts Price Target on GT Biopharma to $5 From $25, Reiterates Buy Rating
Analysts Offer Insights on Healthcare Companies: Dynavax (DVAX), Ascendis Pharma (ASND) and GT Biopharma (GTBP)
GT Biopharma Price Target Cut to $5.00/Share From $25.00 by HC Wainwright & Co.
GT Biopharma Is Maintained at Buy by HC Wainwright & Co.